Enterprise value to EBIT forward of Niagen Bioscience, Inc. – NASDAQ:NAGE
The article title indicates a focus on the Enterprise Value to EBIT forward metric for Niagen Bioscience, Inc. (NASDAQ: NAGE). The content appears to be a stub or a section from a larger financial data platform, providing only the title and navigation/footer information without the actual financial data or analysis.
Freedom Broker initiates Niagen Bioscience stock coverage with buy rating
Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a $9.00 price target, highlighting significant upside potential given its current trading price of $3.49 against an analyst consensus of $10-$18. The firm's investment thesis is supported by Niagen Bioscience's profitability, strong gross profit margin, robust balance sheet, and its position to benefit from the growing longevity economy, GLP-1 adoption, and increased focus on healthspan, along with its expanding Ingredient segment and strong intellectual property. Recent company developments, including increased sales, patent uphold, and the launch of a telehealth platform, further reinforce its market position and growth prospects.
Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com
Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a price target of $9.00, citing significant upside potential from its current trading price of $3.49. The firm's investment thesis is based on secular tailwinds in the longevity economy, expanding its Ingredients segment, and a strong intellectual property portfolio. Recent company developments, including sales increases, patent enforcement, and a new telehealth platform, further support the positive outlook.
Implied Volatility Surging for Niagen Bioscience Stock Options
Implied volatility for Niagen Bioscience (NAGE) stock options is surging, particularly for the August 21, 2026 $12.50 Call, indicating that the market expects significant price movement. Despite this, analysts currently rate NAGE as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates, suggesting potential trading opportunities for options traders. This high implied volatility, coupled with analyst sentiment, might signal a big upcoming event or a strategy for experienced traders to sell premium.
NAGE - Niagen Bioscience Inc Options
This page provides a detailed financial overview of Niagen Bioscience Inc (NAGE), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key metrics such as P/E, EPS, insider and institutional ownership, profitability, and analyst recommendations. The data indicates recent stock price changes, dividend information, and growth rates.
If You Invested $1,000 in Niagen Bioscience, Inc (NAGE)
This article analyzes the historical performance of investing $1,000 in Niagen Bioscience, Inc. (NAGE) over different periods. It provides an overview of Niagen Bioscience, detailing its focus on NAD+ science and healthy-aging research through patented ingredients like Niagen®, consumer products like Tru Niagen, clinical-grade offerings, and its robust intellectual property portfolio. The company's financials, market activities, and strategic positioning within the biotechnology sector are also covered.
H.C. Wainwright reiterates Niagen Bioscience stock rating on patent ruling By Investing.com
H.C. Wainwright has reiterated a Buy rating and an $11.00 price target for Niagen Bioscience (NASDAQ: NAGE) following a favorable patent ruling. The U.S. District Court for the District of Delaware upheld the enforceability of a patent related to crystalline nicotinamide riboside, reinforcing the intellectual property strength for the company. Despite the recent patent news, H.C. Wainwright had previously lowered its price target to $11 from $12, while maintaining its Buy rating after Q1 2026 earnings showed a 5% increase in total net sales to $31.5 million, surpassing forecasts.
Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com
This article announces that Investing.com has published information regarding the Form S-3 filing by Niagen Bioscience Inc for June 29. The brief notice highlights the filing and its publication date. It also provides current stock market data for various indices, commodities, and shares.
Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com
This article announces that Niagen Bioscience Inc. filed a Form S-3 on June 29. It is a brief financial news update from Investing.com, typical of a regulatory filing announcement. The core content is simply the filing information without further details.
Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com
This article announces that a Form S-3 has been filed by Niagen Bioscience Inc. It states the filing is for June 29th and was published by Investing.com. The content is brief and does not provide further details about the S-3 filing.
Form 4 Niagen Bioscience Inc For: 26 June By Investing.com
This article provides an Investing.com report on the Form 4 filing for Niagen Bioscience Inc., dated June 26. It includes standard disclaimers about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the provided data may not be real-time or accurate. The content also notes that Fusion Media and its data providers are not liable for trading losses.
Form 4 Niagen Bioscience Inc For: 26 June By Investing.com
This article reports that Niagen Bioscience Inc. filed a Form 4 for insider transactions on June 26. The piece provides the filing date and company name, along with a stock price update for NAGE. It implies further details about the insider transaction are available within the Form 4 document.
Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45
Niagen Bioscience (NAGE) director Patrick Kristin was granted 31,746 stock options with an exercise price of $3.45 per share. These options will vest 100% on June 24, 2027, and have an expiration date of June 23, 2036. This transaction is classified as an equity compensation award rather than an open-market purchase or sale.
Director at Niagen Bioscience (NAGE) receives 31,746 stock options award
Niagen Bioscience director Ann Cohen was granted 31,746 stock options with an exercise price of $3.45 per share, expiring on June 23, 2036. These options will vest 100% on June 24, 2027. Following this award, Cohen directly holds 31,746 options, as reported in a neutral filing.
Director Steven D. Rubin receives 31,746 Niagen Bioscience (NAGE) stock options
Niagen Bioscience director Steven D. Rubin was granted 31,746 stock options, allowing him to purchase Common Stock at an exercise price of $3.45 per share. These options are a compensation award and will vest 100% on June 24, 2027, with an expiration date of June 23, 2036. This grant means Rubin now holds 31,746 derivative securities and no open-market share purchases or sales were reported in this filing.
Niagen Bioscience (NAGE) director receives grant of 31,746 stock options at $3.45
Niagen Bioscience (NAGE) director Frank L. Jaksch Jr. was granted 31,746 stock options with an exercise price of $3.45 per share. These compensation-related options will vest 100% on June 24, 2027, and expire on June 23, 2036. This transaction involved no open-market buying or selling of shares.
Form 4 Niagen Bioscience Inc For: 26 June By Investing.com
This article reports on a Form 4 filing for Niagen Bioscience Inc. on June 26th. It mentions that shares of Niagen Bioscience Inc. (NAGE) were up 3.32% and provides various market data points and news headlines.
Price to earnings forward of Niagen Bioscience, Inc. – NASDAQ:NAGE
The article focuses on the "Price to earnings forward" financial metric for Niagen Bioscience, Inc. (NASDAQ: NAGE). It notes that there are no current trades for the stock, indicating a focus on financial data rather than active market movements.
Price to sales forward of Niagen Bioscience, Inc. – NASDAQ:NAGE
This article provides the "Price to sales forward" metric for Niagen Bioscience, Inc. (NASDAQ: NAGE). The content is primarily a data placeholder from TradingView, indicating that the specific financial value is not displayed, and only the period, value, and change metrics are listed.
Price to book forward of Niagen Bioscience, Inc. – NASDAQ:NAGE
The article provides the "Price to book forward" for Niagen Bioscience, Inc. (NASDAQ: NAGE) as seen on TradingView. It indicates that the market was closed with no trades at the time of viewing. This page seems to be a financial data point for the company on the platform.
Niagen Bioscience, Inc. Actuals & Estimates (NASDAQ:NAGE)
This article provides an overview of Niagen Bioscience, Inc. (NASDAQ: NAGE) including its latest stock price, financial performance, analyst forecasts, and historical data. It highlights the company's recent stock decline, future earnings estimates, and market capitalization, along with a "strong sell" technical analysis rating.
Niagen Bioscience Inc (NAGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Niagen Bioscience Inc (NAGE), covering its price momentum, support and resistance levels, and various technical indicators and moving averages. The company's current price momentum score is 6.76, placing it 222nd in its industry, with the stock trading between resistance at $3.85 and support at $3.16. Based on the analysis, the overall signal for NAGE from both indicators and moving averages is "Sell."
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications
Niagen Bioscience Inc. (NASDAQ: NAGE) has renamed its ChromaDex External Research Program to the Niagen Research Program, emphasizing its commitment to advancing the understanding and applications of NAD+. The program collaborates with leading independent investigators from institutions like Mayo Clinic and Cambridge University, providing Niagen materials and technical support for over 175 ongoing research studies across various health areas. Niagen Bioscience Inc. is a global bioscience company focused on healthy aging, and they are the innovators and patent holders of Niagen (nicotinamide riboside, or NR).
Niagen Bioscience Inc (NAGE) Institutional Confidence
Niagen Bioscience Inc (NAGE) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry as of June 18, 2026. The institutional shareholding proportion is 38.95%, representing a 23.33% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.67% of outstanding shares.
Niagen Bioscience Inc (NAGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey focuses on the revenue breakdown for Niagen Bioscience Inc (NAGE), specifically by business segment and region. However, the company has not yet disclosed the relevant data for these categories. The page provides current stock information, including market cap and P/E ratio.
Niagen Bioscience Inc (NAGE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Niagen Bioscience Inc (NAGE) with a focus on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The article also presents current trading information for NAGE, including its stock price, market capitalization, and P/E ratio.
Niagen Bioscience Inc (NAGE) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Niagen Bioscience Inc (NAGE), highlighting its current risk assessment score of 6.03, ranking it 29 out of 388 in the Biotechnology & Medical Research industry. Key metrics such as its beta value of 2.19, maximum drawdown, volatility, and Sharpe Ratio are detailed. The report indicates that NAGE's stock tends to be more volatile than the overall market.
Niagen Bioscience Inc (NAGE) Earnings Forecast: Future EPS & Revenue Growth Estimates
Niagen Bioscience Inc (NAGE) has an earnings forecast score of 8.80, placing it 54th in the Biotechnology & Medical Research industry. Analysts have a consensus "Buy" rating with an average price target of $14.00, indicating a potential upside of 267.35%. The company's expected revenue for the next quarter is $31.71 million, and the EPS is projected to be $0.02.
Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall
Analysts have cut combined price targets for Niagen Bioscience (NAGE) by US$5, yet their fair value estimate remains stable at US$12.60. This adjustment comes from firms like H.C. Wainwright, Roth Capital, and Canaccord, who lowered individual price targets while maintaining an overall bullish outlook. The changes reflect fine-tuning of models considering both long-term opportunities and risks for the company.
Niagen Bioscience And 2 Other Promising Penny Stocks To Watch
This article highlights three promising penny stocks—Niagen Bioscience (NAGE), Rocket Pharmaceuticals (RCKT), and MacroGenics (MGNX)—in a robust market with anticipated annual earnings growth of 19%. It details each company's financial health, operational focus, recent developments, and market capitalization, emphasizing their potential for growth despite the typical risks associated with penny stocks. The analysis encourages investors to look for strong fundamentals and growth trajectories in smaller, less established companies.
Niagen Bioscience Inc (NAGE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Niagen Bioscience Inc (NAGE), noting its current valuation score of 8.77 and ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 14.69, comparing it to recent highs and lows. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Niagen Bioscience And 2 Other Promising Penny Stocks To Watch
This article highlights three promising penny stocks—Niagen Bioscience (NAGE), Rocket Pharmaceuticals (RCKT), and MacroGenics (MGNX)—in a robust market. It details each company's financial health, operations, and recent developments, focusing on their potential for growth despite the inherent risks of penny stocks. The piece also provides links to more in-depth reports for each company.
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program
Niagen Bioscience (NAGE) has renamed its research program to Niagen Research Program, focusing on NAD+ science and extensive studies. Despite recent share price declines, the company is considered significantly undervalued at $3.50 against an analyst target of $12.60, with potential for future growth driven by increased R&D and pharmaceutical developments. Investors are encouraged to consider the company's valuation alongside potential risks like regulatory approvals and rising marketing expenses.
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience, a company focused on NAD+ science and healthy aging, announced that its senior management will present at the 16th Annual East Coast IDEAS Investor Conference on Thursday, June 11, 2026, in New York, NY. CEO Rob Fried is scheduled to present, and COO Anjan Parikh will host one-on-one meetings with institutional investors. The presentation will also be livestreamed.
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience, Inc. will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, in New York City. CEO Rob Fried will deliver a presentation, and CFO Ozan Pamir will be available for one-on-one meetings with institutional investors. The company focuses on NAD+ science and healthy aging, offering products like Tru Niagen® and Niagen™ Plus.
Is Niagen Bioscience’s (NAGE) NAD+ Research Push Quietly Redefining Its Competitive Moat?
Niagen Bioscience has rebranded its ChromaDex External Research Program to the Niagen Research Program and launched a Trainee Grant Program, focusing its scientific identity on its patented Niagen ingredient and supporting over 175 NAD+ studies. While this move enhances credibility and deepens the academic moat, it is seen as additive rather than transformative for the company's investment narrative, which still faces questions about growth consistency and market underperformance. Investors must weigh the long-term academic upside against current premium multiples and the need for immediate revenue drivers.
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience has renamed its ChromaDex External Research Program to the Niagen Research Program, aligning with the company's focus on its flagship ingredient, Niagen®. This program has supported over 300 research collaborations and 45 human clinical studies, advancing understanding of NAD+ biology. The initiative continues to support new research and also launched a Trainee Grant Program to foster the next generation of NAD+ scientists.
Inside Niagen's program backing 300+ NAD+ research collaborations
Niagen Bioscience has renamed its ChromaDex External Research Program to the Niagen Research Program to better reflect its focus on advancing NAD+ understanding through its flagship ingredient, Niagen®. This program has supported over 300 research collaborations, resulting in more than 45 published human clinical studies, and currently assists over 175 ongoing studies, including new initiatives like the Trainee Grant Program. The company aims to further global NAD+ science and its applications in healthy aging.
Q4 2025 Niagen Bioscience Inc Earnings Call Transcript
Niagen Bioscience Inc. (NAGE) announced strong financial results for Q4 2025, with revenue growth of 16% year-over-year and full-year net revenue growth of 30%, totaling $129.4 million. The company reported $64.8 million in cash with no debt and secured a patent for NR intravenous formulations. Despite challenges like increased competition and the FDA's stance on NMN, and a missed primary endpoint in a Parkinson's study, the company projects a 10-15% growth rate for 2026.
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Niagen Bioscience (NAGE.US), maintaining a target price of $10. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims
The National Advertising Review Board (NARB) has recommended that Niagen Bioscience, Inc. either modify or discontinue several health-benefit advertising claims for its Tru Niagen NAD+ dietary supplements. This decision follows an appeal by Niagen of an earlier National Advertising Division (NAD) ruling, which found that the clinical studies and claims made for the product, particularly those related to anti-aging, heart, brain, immune, muscle health, and energy, were not sufficiently substantiated for the general population. Niagen has stated it is disappointed but will comply with the NARB's recommendations.
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims
The National Advertising Review Board (NARB) has recommended that Niagen Bioscience, Inc. modify or discontinue several health-benefit claims for its Tru Niagen dietary supplements. This decision follows an appeal from a National Advertising Division (NAD) ruling, initiated by a competitor. NARB found that Niagen's "clinically proven" and various health-benefit claims lacked adequate substantiation, particularly those implying perceptible health benefits beyond cellular effects.
NAGE News | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE)
This article provides recent news for NIAGEN BIOSCIENCE INC (NASDAQ:NAGE), highlighting two key updates. It mentions a share slide after a Q1 earnings miss and spending guidance reported 17 days ago, and a Q4 2025 revenue beat and mixed earnings reported three months ago.
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy?
Niagen Bioscience (NAGE) recently launched its Niagen Plus clinician-directed telehealth platform in the U.S., which offers prescription-only, pharmaceutical-grade Niagen through at-home subcutaneous injection kits. This new direct-to-client model aims to expand its addressable market and reshape its investment narrative, though success hinges on scaling clinic and telehealth adoption to justify increased operating and marketing costs. While analysts project significant revenue and earnings growth by 2029, the company faces risks from competition, regulation, and execution challenges in this new direct-access strategy.
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy?
Niagen Bioscience (NAGE) has launched Niagen Plus, a clinician-directed telehealth platform offering prescription-only Niagen via at-home subcutaneous injection kits. This direct-to-client approach could expand its market and reshape its investment narrative by combining telehealth, home delivery, and medically supervised NAD+ support. The company's recent modest sales and net income increases may support this rollout, but investors should monitor adoption rates to assess the platform's long-term impact and its ability to scale beyond a niche.
HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00
HC Wainwright has lowered its price target for Niagen Bioscience (NASDAQ:NAGE) from $12.00 to $11.00 but maintained a "buy" rating. This adjustment comes despite Niagen Bioscience exceeding Q1 earnings estimates with $0.07 EPS on $31.47 million in revenue. The stock's current trading price of around $4.17 is significantly below the revised analyst targets, with a consensus "Moderate Buy" rating and an average target price of $14.67 among analysts.
A Look At Niagen Bioscience (NAGE) Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch
Niagen Bioscience (NAGE) surpassed Q1 2026 earnings estimates and launched its Niagen Plus telehealth platform and at-home injection kits, yet its stock has seen significant declines over the past year. Despite a popular narrative suggesting the stock is 69.2% undervalued with a fair value of $13.60 per share, growth projections depend on favorable regulatory and supply chain outcomes, introducing both potential and risk. The article encourages investors to conduct further due diligence on the company's prospects.
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results
Niagen Bioscience Inc. (NAGE:NASDAQ) reported strong first-quarter 2026 financial results, including a 3% increase in net sales to US$31.5 million and a gross margin of 63.5%. The company is expanding its product offerings, launching new initiatives like Niagen Plus and Niagen IV, and entering the skincare market. Despite some sales challenges, analysts maintain a "Buy" rating, anticipating future growth driven by e-commerce and strategic expansions, though some price targets have been adjusted.
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced its participation in two upcoming investor conferences in May 2026: the 31st Annual Sohn Investment Conference and the 4th Annual Benchmark Consumer One-On-One Conference. Senior leadership, including CEO Rob Fried and CFO Ozan Pamir, will attend to discuss the company's focus on NAD+ science and healthy aging solutions. This provides an opportunity for investors to engage directly with Niagen Bioscience's management.
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, a leader in NAD+ science and healthy aging, announced that its senior leadership will participate in two upcoming investor conferences: the 31st Annual Sohn Investment Conference and the 4th Annual Benchmark Consumer One-On-One Conference. CFO Ozan Pamir will attend both, while CEO Rob Fried will join the Benchmark conference. The company invites interested parties to schedule one-on-one meetings.
